The Cooper Cos. (NYSE:COO) – KeyCorp issued their FY2018 earnings per share estimates for The Cooper Cos. in a report released on Thursday. KeyCorp analyst M. Mishan forecasts that the brokerage will post earnings per share of $11.06 for the year. KeyCorp has a “Buy” rating and a $221.00 price objective on the stock.

The Cooper Cos. (NYSE:COO) last announced its earnings results on Thursday, September 1st. The medical device company reported $2.30 earnings per share for the quarter, topping analysts’ consensus estimates of $2.29 by $0.01. The business had revenue of $514.70 million for the quarter. The Cooper Cos. had a return on equity of 14.89% and a net margin of 13.14%. The Cooper Cos.’s revenue was up 11.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.97 earnings per share.

A number of other equities analysts also recently issued reports on COO. Robert W. Baird restated an “outperform” rating and issued a $185.00 price target on shares of The Cooper Cos. in a research note on Saturday, June 25th. Stifel Nicolaus raised their price target on The Cooper Cos. from $180.00 to $195.00 and gave the stock a “buy” rating in a research note on Thursday, June 30th. JPMorgan Chase & Co. started coverage on The Cooper Cos. in a research note on Wednesday, July 13th. They issued a “buy” rating on the stock. Piper Jaffray Cos. restated an “overweight” rating and issued a $185.00 price target on shares of The Cooper Cos. in a research note on Tuesday, July 26th. Finally, Zacks Investment Research downgraded The Cooper Cos. from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $183.00.

Shares of The Cooper Cos. (NYSE:COO) traded down 0.75% during trading on Monday, reaching $176.42. The company’s stock had a trading volume of 213,030 shares. The company has a 50 day moving average of $184.03 and a 200 day moving average of $169.84. The company has a market cap of $8.60 billion, a PE ratio of 34.54 and a beta of 0.29. The Cooper Cos. has a 12-month low of $119.28 and a 12-month high of $190.99.

In other The Cooper Cos. news, Director William A. Kozy acquired 270 shares of the stock in a transaction dated Tuesday, September 6th. The shares were acquired at an average cost of $186.69 per share, for a total transaction of $50,406.30. Following the completion of the transaction, the director now directly owns 770 shares of the company’s stock, valued at $143,751.30. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Michael Kalkstein sold 1,000 shares of the business’s stock in a transaction dated Friday, July 8th. The shares were sold at an average price of $178.55, for a total value of $178,550.00. Following the completion of the transaction, the director now owns 14,215 shares in the company, valued at $2,538,088.25. The disclosure for this sale can be found here. 2.20% of the stock is owned by insiders.

Several institutional investors have recently made changes to their positions in COO. Vanguard Group Inc. boosted its stake in shares of The Cooper Cos. by 2.8% in the second quarter. Vanguard Group Inc. now owns 3,644,352 shares of the medical device company’s stock valued at $625,262,000 after buying an additional 100,238 shares during the period. BlackRock Fund Advisors boosted its stake in shares of The Cooper Cos. by 4.7% in the second quarter. BlackRock Fund Advisors now owns 1,709,402 shares of the medical device company’s stock valued at $293,282,000 after buying an additional 75,993 shares during the period. State Street Corp boosted its stake in shares of The Cooper Cos. by 0.5% in the second quarter. State Street Corp now owns 1,557,106 shares of the medical device company’s stock valued at $267,142,000 after buying an additional 8,276 shares during the period. BlackRock Institutional Trust Company N.A. boosted its stake in shares of The Cooper Cos. by 3.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 1,472,668 shares of the medical device company’s stock valued at $252,666,000 after buying an additional 44,626 shares during the period. Finally, Westfield Capital Management Co. LP boosted its stake in shares of The Cooper Cos. by 6.6% in the second quarter. Westfield Capital Management Co. LP now owns 785,363 shares of the medical device company’s stock valued at $134,745,000 after buying an additional 48,718 shares during the period. Institutional investors and hedge funds own 98.67% of the company’s stock.

The Cooper Cos. Company Profile

The Cooper Companies, Inc (Cooper) is a medical device company. The Company operates through two business units: CooperVision, Inc (CooperVision) and CooperSurgical, Inc (CooperSurgical). CooperVision develops, manufactures and markets a range of soft contact lenses for the vision correction market. CooperVision offers Biofinity monthly spherical, toric and multifocal lenses under the Avaira brand.

5 Day Chart for NYSE:COO

Receive News & Stock Ratings for The Cooper Cos. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Cooper Cos. and related stocks with our FREE daily email newsletter.